Literature DB >> 34520406

Recent clinical trials in atrial fibrillation.

Thomas Flautt1, Miguel Valderrábano.   

Abstract

PURPOSE OF REVIEW: Management of atrial fibrillation can be overwhelming with the amount of information and treatment options available today. This review discusses landmark and other clinically relevant trials published in the last 18 months. RECENT
FINDINGS: There have been several recent key clinical trials and subanalyses in the field of atrial fibrillation. Early rhythm control with ablation or antiarrhythmic medications has upended the previous practice of rate control for patients with atrial fibrillation. Vein of Marshall alcohol ablation in combination with endocardial mitral annular ablation and a hybrid epicardial/endocardial approach has shown promising results in the fight against persistent atrial fibrillation. Early ablation with cryoballoon therapy vs. antiarrhythmic therapy gives further evidence for early ablation in patients with symptomatic paroxysmal atrial fibrillation.
SUMMARY: The rapid development in technology and medications to treat atrial fibrillation, prevent stroke and improve quality of life for patients has created a vast amount of information for physicians to process. The present review will focus on the recent (within 2 years) clinical trials in atrial fibrillation and the impact they may have on your practice.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 34520406      PMCID: PMC8713141          DOI: 10.1097/HCO.0000000000000914

Source DB:  PubMed          Journal:  Curr Opin Cardiol        ISSN: 0268-4705            Impact factor:   2.108


  22 in total

1.  Cryoballoon or Radiofrequency Ablation for Atrial Fibrillation Assessed by Continuous Monitoring: A Randomized Clinical Trial.

Authors:  Jason G Andrade; Jean Champagne; Marc Dubuc; Marc W Deyell; Atul Verma; Laurent Macle; Peter Leong-Sit; Paul Novak; Mariano Badra-Verdu; John Sapp; Iqwal Mangat; Clarence Khoo; Christian Steinberg; Matthew T Bennett; Anthony S L Tang; Paul Khairy
Journal:  Circulation       Date:  2019-10-21       Impact factor: 29.690

2.  Pulsed Field Ablation for Pulmonary Vein Isolation in Atrial Fibrillation.

Authors:  Vivek Y Reddy; Petr Neuzil; Jacob S Koruth; Jan Petru; Moritoshi Funosako; Hubert Cochet; Lucie Sediva; Milan Chovanec; Srinivas R Dukkipati; Pierre Jais
Journal:  J Am Coll Cardiol       Date:  2019-05-11       Impact factor: 24.094

3.  Effect of Catheter Ablation vs Medical Therapy on Quality of Life Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial.

Authors:  Daniel B Mark; Kevin J Anstrom; Shubin Sheng; Jonathan P Piccini; Khaula N Baloch; Kristi H Monahan; Melanie R Daniels; Tristram D Bahnson; Jeanne E Poole; Yves Rosenberg; Kerry L Lee; Douglas L Packer
Journal:  JAMA       Date:  2019-04-02       Impact factor: 56.272

4.  Early Rhythm-Control Therapy in Patients with Atrial Fibrillation.

Authors:  Paulus Kirchhof; A John Camm; Andreas Goette; Axel Brandes; Lars Eckardt; Arif Elvan; Thomas Fetsch; Isabelle C van Gelder; Doreen Haase; Laurent M Haegeli; Frank Hamann; Hein Heidbüchel; Gerhard Hindricks; Josef Kautzner; Karl-Heinz Kuck; Lluis Mont; G Andre Ng; Jerzy Rekosz; Norbert Schoen; Ulrich Schotten; Anna Suling; Jens Taggeselle; Sakis Themistoclakis; Eik Vettorazzi; Panos Vardas; Karl Wegscheider; Stephan Willems; Harry J G M Crijns; Günter Breithardt
Journal:  N Engl J Med       Date:  2020-08-29       Impact factor: 91.245

5.  Effect of Renal Denervation and Catheter Ablation vs Catheter Ablation Alone on Atrial Fibrillation Recurrence Among Patients With Paroxysmal Atrial Fibrillation and Hypertension: The ERADICATE-AF Randomized Clinical Trial.

Authors:  Jonathan S Steinberg; Vitaliy Shabanov; Dmitry Ponomarev; Denis Losik; Eduard Ivanickiy; Evgeny Kropotkin; Konstantin Polyakov; Pawel Ptaszynski; Boris Keweloh; Christopher J Yao; Evgeny A Pokushalov; Alexander B Romanov
Journal:  JAMA       Date:  2020-01-21       Impact factor: 56.272

6.  Hemolysis of human erythrocytes by transient electric field.

Authors:  K Kinosita; T T Tsong
Journal:  Proc Natl Acad Sci U S A       Date:  1977-05       Impact factor: 11.205

7.  Effect of Catheter Ablation With Vein of Marshall Ethanol Infusion vs Catheter Ablation Alone on Persistent Atrial Fibrillation: The VENUS Randomized Clinical Trial.

Authors:  Miguel Valderrábano; Leif E Peterson; Vijay Swarup; Paul A Schurmann; Akash Makkar; Rahul N Doshi; David DeLurgio; Charles A Athill; Kenneth A Ellenbogen; Andrea Natale; Jayanthi Koneru; Amish S Dave; Irakli Giorgberidze; Hamid Afshar; Michelle L Guthrie; Raquel Bunge; Carlos A Morillo; Neal S Kleiman
Journal:  JAMA       Date:  2020-10-27       Impact factor: 56.272

8.  Determinants of outcome impact of vein of Marshall ethanol infusion when added to catheter ablation of persistent atrial fibrillation: A secondary analysis of the VENUS randomized clinical trial.

Authors:  Adi Lador; Leif E Peterson; Vijay Swarup; Paul A Schurmann; Akash Makkar; Rahul N Doshi; David DeLurgio; Charles A Athill; Kenneth A Ellenbogen; Andrea Natale; Jayanthi Koneru; Amish S Dave; Irakli Giorgberidze; Hamid Afshar; Michelle L Guthrie; Raquel Bunge; Carlos A Morillo; Neal S Kleiman; Miguel Valderrábano
Journal:  Heart Rhythm       Date:  2021-01-19       Impact factor: 6.779

Review 9.  Cabins, castles, and constant hearts: rhythm control therapy in patients with atrial fibrillation.

Authors:  Stephan Willems; Christian Meyer; Joseph de Bono; Axel Brandes; Lars Eckardt; Arif Elvan; Isabelle van Gelder; Andreas Goette; Michele Gulizia; Laurent Haegeli; Hein Heidbuchel; Karl Georg Haeusler; Josef Kautzner; Lluis Mont; G Andre Ng; Lukasz Szumowski; Sakis Themistoclakis; Karl Wegscheider; Paulus Kirchhof
Journal:  Eur Heart J       Date:  2019-12-07       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.